Broad cancer panel with focus on therapeutically targetable mutations for liquid biopsy samples

GATCLIQUID ONCOPANEL is a comprehensive gene panel for analysis of tumour-associated mutations. The product combines single molecule PCR target enrichment and next-generation sequencing (NGS) of liquid biopsy samples to generate a detailed profile of driver mutations that are crucial for efficient cancer screening. The panel consists of fifty well-established cancer genes, including tumour suppressors, mutation hotspots and drug resistance markers. The covered cancer genes were carefully chosen based on their clinical relevance.


  • Screening of circulating tumour DNA (ctDNA) for key cancer drivers 
  • Target enrichment of more than 200 amplicons from 50 known cancer genes via single molecule PCR
  • Industry leading sequence coverage and uniformity
  • Limit of quantification (LOQ) down to an allele frequency of 1%

Service required

GATCLIQUID ONCOPANEL incl. 5.000x on target coverage and variant analysis

Pre-Sequencing required

Isolation of cell-free DNA

Bioinformatic analysis



You need to login to see product price
  • {{label}}:{{options}}
{{qty}} x {{name}}
{{qty}} x {{name}}

ISO9001 Certificate - GATC BiotechISO17025 Accreditation - GATC BiotechIllumina Certified Service Provider - GATC Biotech

Product Details

Product details

Full service package offered by GATCLIQUID ONCOPANEL includes the following:

  • Non-invasive, real-time screening of cancer entities for key cancer drivers like tumour suppressors, mutation hotspots in tumour activators, drug resistance biomarkers
  • Optimised protocols for low-input ctDNA extraction from plasma samples
  • NGS of large cancer panel, containing more than 200 targets from 50 clinically relevant cancer genes
  • Superior sequence coverage and uniformity
  • Quantification with minor allele frequencies as low as 1%

Accepted starting material for GATCLIQUID ONCOPANEL

  • 4 ml plasma

Technology used for GATCLIQUID ONCOPANEL

  • Target enrichment: single molecule PCR
  • Next-generation sequencing: Illumina


  • GATC Data Analysis Report containing detailed workflow descriptions and a clearly labeled table of all results

The product is available for research use only (RUO).

Additional Information

Our complete Diagnostic Solution for gene panel analysis of plasma ctDNA provides clinicians and researchers a powerful non-invasive testing tool for effective cancer diagnostics. Proprietary workflows for isolation of low-amounts of circulating tumour DNA are applied to derive the most information from liquid biopsy samples.

Cutting-edge PCR technologies are used for enrichment of a wide range of cancer-related targets, ensuring tumour heterogeneity can be capably captured. The panel is subsequently sequenced with the leading NGS technology incorporating a minimum sequencing error rate. Results are analysed by a team of experienced specialists to deliver confident, clear-cut answers.

ONCOPANEL - workflow

Typical applications for GATCLIQUID ONCOPANEL include:

  • Non-invasive screening for clinically relevant tumour-associated mutations in real-time
  • Comparison of matched samples from tissue biopsies and liquid biopsies
  • Research on mechanisms of cancer progression
  • Selection of the most-relevant mutation for follow-up studies with GATCLIQUID ONCOTARGET

ONCOPANEL - list of genes
Table 1. List of genes included in ONCOPANEL

GATCLIQUID ONCOPANEL can be used for clinical applications like:

  • Therapy decision making
  • Biomarker and drug target discovery
  • Patient stratification in clinical trials
  • Post-treatment follow-up, especially in cases where multiple mutations are present

The product is available for research use only (RUO).


1. What kind of samples can be processed with GATCLIQUID ONCOPANEL?
For ONCOPANEL, we accept fresh or retained plasma samples. Please refer to our GATCLIQUID sample preparation sheet (see "Files" section). The extraction of ctDNA is performed from the blood plasma fraction.
For starting material like DNA isolated from FFPE and tissue samples, please refer to our product INVIEW ONCOPANEL aimed at solid tumour profiling.

2. How much starting material is required?
We recommend the delivery of 4 ml plasma sample.

3. How is the target enrichment performed?
The genes of interests are enriched via targeted single-molecule picodroplet PCR that yields improved sequence uniformity and more complete coverage (greater than 99%). Each PCR droplet contains the same amount of ctDNA, primers and master mix, resulting in highly uniform singleplex PCR products. These are then subjected to next-generation sequencing.

4. What kind of mutations can be detected with GATCLIQUID ONCOPANEL?
The product interrogates more than 200 amplicons for single nucleotide polymorphisms (SNP).

5. What is the sensitivity of the product?
The product has a sensitivity of about 1%.

6. What kind of quality controls do you perform?
The quality and quantity of each sample will be determined at sample receipt. Further quality controls are performed at various steps of the process.

All three tests are based on liquid biopsy. The three products serve as powerful non-invasive tools for real-time cancer profiling with the ability to capture the entire heterogeneity of the disease.

GATCLIQUID ONCOEXOME is the first commercially available service for whole exome sequencing (WES) of ctDNA. With this service, a comprehensive profile of all mutations present in the protein coding regions of the genome is obtained. This product is suitable for a first look at the genome of a suspected cancer patient, in cases where limited information regarding clinically relevant mutations is available.

GATCLIQUID ONCOPANEL is a comprehensive NGS cancer panel for profiling important tumour-specific mutations. It uses single molecule PCR to target 50 known cancer genes including tumour suppressors, mutation hotspots and drug resistance markers. The panel sets a new industry standard in terms of sequence coverage and uniformity with a sensitivity of about 1%.

GATCLIQUID ONCOTARGET facilitates ultra-sensitive detection of clinically relevant cancer-specific point mutations, insertions, deletions and gene fusions in circulating tumour DNA down to an allele frequency of 0.1%. This approach is suitable for treatment monitoring as it has the appropriate sensitivity to detect a relapse at a very early stage.

8. Where do I get my results and in which form are they delivered?
All deliverables can be downloaded via your secure myGATC online account.

9. How soon after the blood draw should I ship the sample?
Blood samples have to be shipped to GATC Biotech within 24 hours after blood drawing. The sample must be stored in BCT Streck tubes. Storage and delivery is possible at room temperature. Plasma samples have to be shipped on dry ice.

10. How many samples can I submit?
GATC Biotech accepts any number of samples starting from one sample.

11. Where should I send my samples?
Please post your samples to:
GATC Biotech AG
European Genome and Diagnostics Centre
Jakob-Stadler-Platz 7
78467 Konstanz

Please do not use GATC Collection Points for shipment of NextGen samples, because this will cause delay in sample arrival at the appropriate destination!


Product Inquiry